🔗 Share this article

As the US continues making unprecedented revisions to its vaccine schedules, a particular individual appears unexpectedly: Dr. Tracy Beth Høeg, a US-based physician and epidemiologist who rose to prominence by expressing skepticism about coronavirus vaccines in the pandemic and has zeroed in on alleged deaths following Covid immunization in her short tenure at the US Food and Drug Administration (FDA).

Proposed Shifts to Childhood Immunization Schedule

Public health authorities were set to reveal radical changes to the childhood immunization program earlier this month, synchronizing the US with the Danish immunization schedule, according to reports – a substantial departure that would put the US at odds with many the world with no evidence for benefit. This reveal has been pushed back until the coming year.

Rather than Vinay Prasad, Dr. Høeg is listed to address the audience at the meeting. She was just designated acting director of the FDA’s CDER, the fifth individual to lead the division this calendar year.

A New Direction at the FDA

Høeg's temporary position might represent a closer partnership between the pharmaceutical and vaccine branches as Høeg and Prasad solidify control at the regulatory agency – and it points to a renewed priority upon reevaluating already-approved vaccines at the FDA.

The new acting director has often pushed for discontinuing certain pediatric immunization guidelines in the US in order to be more like the Danish model, a nation with nationalized medicine and a population approximately the size of Wisconsin’s.

To date comments, she has continued to focus on vaccination policy – usually the responsibility of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Questions Over Background

The appointee has no obvious track record in drug development, oversight or leadership, which has been typical for previous heads of the biologics center. She has worked at the FDA as a senior adviser to the FDA chief and the vaccine center since earlier this year.

“It seems she lacks to have the necessary background” for overseeing the CDER, said Jonathan Howard. “She’s never run a clinical trial. She lacks experience in managing a large organization. She lacks background in pharmaceutical oversight.”

Past heads of CBER would “understand legal statutes and the research of drug development”, commented Dr. Janet Woodcock. “Frankly, she has not acquired the sort of resume that previous people who headed CBER have had.”

CDER has an immense portfolio at the agency, Woodcock emphasized.

“Many people just zeroes in on the innovative therapies, but the generic program clears a multitude of generic drugs. There’s a biosimilars program, non-prescription drug unit and more, and all of those have to be managed,” Dr. Woodcock said. “The area you overlook, that is the part that I always told people is going to bite you.”

Furthermore, a significant administrative element to the position, which manages over 5,000 employees. “It’s a huge management job, if you do it right,” Woodcock concluded.

Agency Reaction and Controversial Programs

When asked about concerns about Høeg’s qualifications and whether this assignment indicates increased cooperation among regulatory chiefs on immunizations, a press secretary responded that the “inquiries stem from inaccurate assumptions”.

“Her resume is consistent with the duties of her role,” the official stated, pointing to the time Høeg spent counseling the agency head on “pharmaceutical safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Høeg assumes responsibility for the commissioner’s recently launched priority voucher program, a disputed expedited drug-approval program that reportedly worried her predecessors. “By what process are these drugs being picked for this voucher program? Who is making the decisions?” Dr. Howard questioned. “There is a lot of lack of transparency going on at the agency right now.”

Broadly speaking, he stated, “the agency seems to be moving towards more relaxed rules of all drugs, with the exception of shots.”

Documented Past Work on Vaccines

Concerning immunizations, Høeg has a more established, if troubling, history, some experts said. She authored a analysis using non-validated crowd-sourced reports to estimate the incidence of heart inflammation after Covid immunization. She consulted for the state of Florida chief medical officer Joseph Ladapo, who allegedly have altered data to imply Covid vaccines are riskier than they are.

Part of her “wish list” for the current administration encompassed changing rules for novel immunizations and ending “unnecessary” vaccines, she stated post-election on a audio program. At the FDA, Dr. Høeg has reportedly suggested preventing adolescent males from obtaining COVID-19 vaccines.

“She’s an thorough dogmatist who starts off with her preconceived notions and works backwards to fit the science in a very disingenuous, fraudulent fashion,” Dr. Howard said.

Taking Control and a “Revenge Tour”

Dr. Høeg joined fellow contrarians, {like|